Traws Pharma Q2 FY26 net loss widens to $3.0 million; revenue logs no revenue

PUBT · 1d ago
Traws Pharma Q2 FY26 net loss widens to $3.0 million; revenue logs no revenue
  • Traws Pharma posted a Q2 net loss of USD 3.05 million, widening from a USD 915,000 loss a year earlier.
  • Revenue was no revenue, versus USD 2.73 million a year earlier, on non-recurring deferred revenue recognized in Q2 2025.
  • R&D expense fell 52.01% to USD 1.1 million, while G&A climbed more than doubled to USD 3.48 million.
  • Cash and cash equivalents rose to USD 5.02 million at June 30, up from USD 3.82 million at Dec. 31.
  • Plans MHRA resubmission for tivoxavir marboxil by end-Q3 2026; CEO Iain Dukes said it is moving quickly on a revised toxicology package.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141630PRIMZONEFULLFEED9810554) on August 14, 2026, and is solely responsible for the information contained therein.